To assess the potential benefit of targeting androgen signaling in AR-positive RCC, Lee et al., implanted AR-positive RCC cells in mice, and treated them with enzalutamide, an AR inhibitor, or abiraterone acetate (AA), a CYP17A1 (Cytochrome P450 17A1) inhibitor that suppresses the production of androgens [68]. Here, AR is linked to renal cell adenocarcinoma.